3Billion

3Billion EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3Billion (394800.KQ) as of Oct 17, 2026 is -5.89 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -6.16 B KRW — a change of -4.43% (higher).

EBITDA

-5.89 BKRW

YoY

-4.43%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3Billion is 2025 -5.89 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3Billion was 2024 -6.16 B KRW. It decreases by -4.43% higher compared to the previous year.

The 3Billion EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
-6.70 B KRW
Jan 1, 2022
-7.27 B KRW
Jan 1, 2023
-6.93 B KRW
Jan 1, 2024
-6.16 B KRW
Jan 1, 2025
-5.89 B KRW
The 3Billion EBITDA history
YEAREBITDAYoY
-5.89 BKRW-4.43%
-6.16 BKRW-11.03%
-6.93 BKRW-4.77%
-7.27 BKRW+8.59%
-6.70 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

3Billion Stock analysis

What does 3Billion do? 3Billion Inc is a company based in Seoul, South Korea, with its headquarters located in the city. The company has a ticker symbol of 394800.KQ and an ISIN of KR7394800007. It went public through an IPO on November 14, 2024. 3Billion Inc operates in the field of genetic testing services, focusing on rare genetic disease diagnostic testing. The company is involved in the research and development of technology designed to automatically assess the pathogenicity of various genetic variants within the genome. Its website is https://3billion.io/. The company's sector and industry classifications are listed as N/A, indicating that these details are not specified in the provided information. No additional details regarding founding year, key personnel, acquisitions, or specific financial figures are available from the given data. The company's primary activities center around the provision of diagnostic services and technological innovation in genetic analysis, aiming to support medical professionals and patients through advanced genetic testing solutions. 3Billion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3Billion stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3Billion is -5.89 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3Billion changed from -6.16 B KRW to -5.89 B KRW, representing a -4.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) 3Billion since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s 3Billion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — 3Billion

All Key Metrics — 3Billion